Single Phase 3 Trial Secures FDA Approval for Novel Gonorrhea Antibiotic

Entasis Therapeutics has established a regulatory precedent that anti-infective development teams will study closely: a single, multinational Phase 3 trial was sufficient to support FDA approval of NUZOLVENCE (zoliflodacin), a first-in-class spiropyrimidinetrione bacterial type II topoisomerase inhibitor indicated for uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae. Approved on December 12, 2025, the approval signals that FDA remains willing to accept streamlined evidence packages for novel antibiotics addressing serious public health needs, provided the trial design is methodologically sound.

The pivotal trial (NCT03959527) enrolled 930 adult and adolescent patients across 16 sites in five countries: South Africa, Thailand, the United States, the Netherlands, and Belgium. The study was a randomized, open-label, noninferiority design. Patients were randomized 2:1 to receive either a single 3 g oral dose of NUZOLVENCE or combination therapy consisting of a single intramuscular 500 mg dose of ceftriaxone plus a single 1 g oral dose of azithromycin. The efficacy population comprised 744 patients who had a confirmed positive N. gonorrhoeae culture at baseline with demonstrated susceptibility to ceftriaxone or azithromycin. The trial population skewed heavily male (88%), with a median age of 27 years; 55% were Black or African American and 31% were Asian, with only 17% of patients enrolled from U.S. sites.

For QA directors and regulatory affairs leads, the trial architecture carries operational implications. The open-label, noninferiority framework against a dual-antibiotic comparator arm reflects current ICH and FDA guidance expectations for antibacterial drug development, and the multinational enrollment strategy directly addresses the diversity requirements increasingly embedded in FDA review. The indication is tightly scoped: patients 12 years of age and older weighing at least 35 kg, with a single-dose oral granule formulation, which simplifies both the clinical use case and the manufacturing release profile.

NUZOLVENCE is administered as a single packet of granules mixed with water and taken as a single oral dose, a delivery format that has direct implications for supply chain, serialization, and unit-dose packaging compliance under 21 CFR Part 211. Plant heads preparing for commercial launch should note the single-dose, single-packet configuration when scoping GMP batch release procedures and sterility assurance protocols for the granule dosage form.

Source: FDA Drug Trials Snapshot: NUZOLVENCE, published April 23, 2026. Refer to the NUZOLVENCE Prescribing Information for all approved conditions of use.